Oncology Nursing Society Congress | Conference

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

April 14th 2025

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

CEPHEUS Data Support D-VRd in Transplant-Ineligible or -Deferred Patients With Myeloma Who Can Tolerate Bortezomib

April 13th 2025

D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.

Cilta-Cel Yields QOL Benefits and Prolonged Treatment-Free Intervals vs SOC in R/R Myeloma

April 12th 2025

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Retrospective Study Shows Variability of Interventions for Blinatumomab-Related Neurotoxicity in Hematologic Malignancies

April 11th 2025

A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.

Aguilar-Clancy on the Importance of Individualized Nutritional Support as a Component of Oncology Care

April 11th 2025

Claudia Aguilar Clancy, FNP-C, AOCNP, discusses the importance of individualized nutritional support as a component of oncology care.

Dr Kozek on Oncology Nurses’ Perceived Difficulties in Providing Palliative Care to Adult Patients

April 11th 2025

Caroline Kozek, DNP, RN, AGNP-C, OCN, discusses a study assessing oncology nurses’ perceived difficulties in providing palliative care to adult patients.

Daratumumab Significantly Reduces Progression Risk in High-Risk Smoldering Multiple Myeloma

April 11th 2025

Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.

Educational Intervention Seeks to Decrease Barriers to Cancer Clinical Trial Enrollment

April 11th 2025

Cancer clinical trial education is valuable and may promote current and future participation.

Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma

April 11th 2025

Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration

April 10th 2025

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

Dr Mahon on the Importance of Integrating Genomic Science Into Oncology Practice

April 10th 2025

Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN, discusses the importance of integrating genomic science into oncology practice.

Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX

April 10th 2025

The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.

Social Determinants of Health Significantly Affect Some Psychoneurological Symptoms in Breast Cancer Survivors

April 10th 2025

Social factors including financial needs and stress caused increased levels of psychoneurological symptoms in breast cancer survivors.

A Mount Sinai Steering Committee Helps Merge Clinical Trials Into the SOC in Oncology

April 10th 2025

A clinical trial steering committee from the Mount Sinai Health System helped integrate therapeutic clinical trials into the SOC for patients with cancer.

Antidiarrheal Medication Is Crucial for Mitigating NALIRIFOX-Related Diarrhea in Metastatic PDAC

April 10th 2025

Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.

Dr Lee on the Role of Integrative Medicine in Oncology Care

April 10th 2025

Richard Lee, MD, FASCO, discusses the role of integrative medicine in oncology care.

Subcutaneous Nivolumab Sustains Comparable Efficacy, Safety to IV Formulation in Advanced ccRCC

April 10th 2025

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC

April 10th 2025

ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.

Tailored Interventions Are Needed to Reduce Barriers to Breast Cancer Screening in Jordan

April 10th 2025

A study identified individual and non-individual factors as barriers to breast cancer screening for women in Jordan.

Niraparib Improves or Maintains HRQOL in Metastatic Castration-Resistant Prostate Cancer

May 7th 2022

Niraparib was found to maintain or improve health-related quality of life in patients with advanced or metastatic castration-resistant prostate cancer, according to data from the final analysis of the phase 2 GALAHAD trial.